[go: up one dir, main page]

PE20020419A1 - Tiadiazoles y oxadiazoles como inhibidores de fosfodiesterasa-7 (pde7) - Google Patents

Tiadiazoles y oxadiazoles como inhibidores de fosfodiesterasa-7 (pde7)

Info

Publication number
PE20020419A1
PE20020419A1 PE2001000964A PE2001000964A PE20020419A1 PE 20020419 A1 PE20020419 A1 PE 20020419A1 PE 2001000964 A PE2001000964 A PE 2001000964A PE 2001000964 A PE2001000964 A PE 2001000964A PE 20020419 A1 PE20020419 A1 PE 20020419A1
Authority
PE
Peru
Prior art keywords
alkylene
alkyl
cycloalkyl
phenyl
thadiazol
Prior art date
Application number
PE2001000964A
Other languages
English (en)
Inventor
Fabrice Vergne
Pierre Ducrot
Charles Andrianjara
Patrick Bernardelli
Edwige Lorthois
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020419A1 publication Critical patent/PE20020419A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A TIAZOLES Y OXADIAZOLES DE FORMULA I DONDE Y ES O, S; R1 ES ALQUILO C4-C10, ALQUENILO C2-C10, ALQUINILO C2-C10, CICLOALQUILO, HETEROCICLO, ARILO SUSTITUIDO CON X1-R4, ENTRE OTROS; R4 ES H, O, NOS, CH, HALOGENO, HALOALQUILO, COOR5 ENTRE OTROS; R2 ES ALQUILO, ALQUENILO C2-C10, ALQUINILO C4-C10, CICLOALQUILO, CICLOALQUENILO, HETEROCICLO, SUSTITUIDO CON H, BIOISOSTERO DE ACIDO CARBOXILICO, HALOALQUILO, COOR5, ENTRE OTROS; R3 ES X2-R'3 DONDE X2 ES ALQUILENO C1-C4, ALQUENILENO C2-C6, ALQUINILENO C2-C6 CON H, ALQUILO C1-C3, CICLOALQUILO C3-C4, ENTRE OTROS; R' ES CICLOALQUILO, CICLOALQUENILO, ARILO, HETEROCICLO, ENTRE OTROS; X3 ES ALQUILENO, ALQUENILENO C2-C6, ALQUINILENO C2-C6, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 3-[5-(4-CLORO-FENIL)-3-METIL-3H-[1,3,4]TIADIAZOL-2-ILIDENAMINO]-BENZOICO, ACIDO (1R*, 2R*)-2-[5-(4-CLORO-FENIL)-3-METIL-3H-[1,3,4]TIADIAZOL-2-ILIDENAMINO]-CICLOHEXANOCARBOXILICO, (S)-2-[5-(4-CLORO-FENIL)-3-METIL-3H-[1,3,4]TIADIAZOL-2-ILIDENAMINO]-2-FENIL-ETANOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA FOSFODIESTERASA-7 PDE7 Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, AUTOINMUNES, RESPIRATORIAS
PE2001000964A 2000-10-02 2001-09-27 Tiadiazoles y oxadiazoles como inhibidores de fosfodiesterasa-7 (pde7) PE20020419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
PE20020419A1 true PE20020419A1 (es) 2002-07-18

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000964A PE20020419A1 (es) 2000-10-02 2001-09-27 Tiadiazoles y oxadiazoles como inhibidores de fosfodiesterasa-7 (pde7)

Country Status (43)

Country Link
US (1) US7122565B2 (es)
EP (2) EP1193261A1 (es)
JP (1) JP4177098B2 (es)
KR (1) KR100614158B1 (es)
CN (1) CN1639141A (es)
AP (1) AP1541A (es)
AR (1) AR035347A1 (es)
AT (1) ATE304003T1 (es)
AU (2) AU2001289945B2 (es)
BG (1) BG107654A (es)
BR (1) BR0114391A (es)
CA (1) CA2424279A1 (es)
CZ (1) CZ2003857A3 (es)
DE (1) DE60113283T2 (es)
DK (1) DK1326853T3 (es)
DZ (1) DZ3440A1 (es)
EA (1) EA007179B1 (es)
EC (1) ECSP034534A (es)
EE (1) EE200300134A (es)
ES (1) ES2247166T3 (es)
GE (1) GEP20053459B (es)
GT (1) GT200100196A (es)
HN (1) HN2001000217A (es)
HR (1) HRP20030247A2 (es)
HU (1) HUP0301248A3 (es)
IL (1) IL155122A0 (es)
IS (1) IS6759A (es)
MA (1) MA25916A1 (es)
MX (1) MXPA03002839A (es)
NO (1) NO20031482D0 (es)
NZ (1) NZ524852A (es)
OA (1) OA12518A (es)
PA (1) PA8529501A1 (es)
PE (1) PE20020419A1 (es)
PL (1) PL366332A1 (es)
PT (1) PT1326853E (es)
SI (1) SI1326853T1 (es)
SK (1) SK3812003A3 (es)
SV (1) SV2003000633A (es)
TN (1) TNSN01139A1 (es)
WO (1) WO2002028847A1 (es)
YU (1) YU24503A (es)
ZA (1) ZA200302346B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
PL1775298T3 (pl) 2004-07-01 2013-08-30 Daiichi Sankyo Co Ltd Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP2139475B1 (en) 2007-03-27 2014-12-17 Omeros Corporation PDE7 inhibitors for use in the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US20120115849A1 (en) 2010-11-08 2012-05-10 Demopulos Gregory A Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
JP6855466B2 (ja) * 2015-06-12 2021-04-07 オリゾン ジェノミックス ソシエダッド アノニマ Lsd1阻害剤に関連するバイオマーカーおよびそれらの使用
HUE066069T2 (hu) 2016-12-16 2024-07-28 Baxter Int Mikafungin készítmények
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
EP4572765A1 (en) 2022-08-18 2025-06-25 Mitodicure GmbH Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (es)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
DE69909592T4 (de) * 1998-02-17 2005-03-24 Roche Diagnostics Gmbh Verwendung von thiadiazolo[4,3-a]pyridine derivaten

Also Published As

Publication number Publication date
ES2247166T3 (es) 2006-03-01
HN2001000217A (es) 2002-06-13
US7122565B2 (en) 2006-10-17
DZ3440A1 (fr) 2002-04-11
AP2003002764A0 (en) 2003-03-31
YU24503A (sh) 2006-03-03
SV2003000633A (es) 2003-04-03
GT200100196A (es) 2002-07-18
EA007179B1 (ru) 2006-08-25
CZ2003857A3 (cs) 2004-02-18
PA8529501A1 (es) 2003-06-30
GEP20053459B (en) 2005-02-25
WO2002028847A1 (en) 2002-04-11
EP1326853B1 (en) 2005-09-07
IS6759A (is) 2003-03-27
BR0114391A (pt) 2003-06-24
IL155122A0 (en) 2003-10-31
CA2424279A1 (en) 2002-04-11
DE60113283T2 (de) 2006-06-08
EE200300134A (et) 2003-08-15
US20030045557A1 (en) 2003-03-06
DE60113283D1 (de) 2005-10-13
OA12518A (en) 2006-05-29
TNSN01139A1 (en) 2005-11-10
KR100614158B1 (ko) 2006-08-21
PL366332A1 (en) 2005-01-24
PT1326853E (pt) 2005-11-30
ATE304003T1 (de) 2005-09-15
HUP0301248A2 (hu) 2003-10-28
EA200300333A1 (ru) 2003-10-30
JP4177098B2 (ja) 2008-11-05
EP1326853A1 (en) 2003-07-16
ECSP034534A (es) 2003-07-25
AP1541A (en) 2006-01-11
MXPA03002839A (es) 2004-09-10
SK3812003A3 (en) 2004-05-04
NO20031482L (no) 2003-04-01
ZA200302346B (en) 2004-08-04
AU2001289945B2 (en) 2005-12-22
HRP20030247A2 (en) 2005-04-30
NO20031482D0 (no) 2003-04-01
AU8994501A (en) 2002-04-15
AR035347A1 (es) 2004-05-12
SI1326853T1 (sl) 2005-12-31
DK1326853T3 (da) 2005-12-12
CN1639141A (zh) 2005-07-13
EP1193261A1 (en) 2002-04-03
JP2004510769A (ja) 2004-04-08
BG107654A (bg) 2003-12-31
KR20030068542A (ko) 2003-08-21
NZ524852A (en) 2004-09-24
MA25916A1 (fr) 2003-10-01
HUP0301248A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
PE20020419A1 (es) Tiadiazoles y oxadiazoles como inhibidores de fosfodiesterasa-7 (pde7)
ES2314418T3 (es) Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias.
RU2011106374A (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
AR035631A1 (es) Compuestos quimicos
PE20091339A1 (es) Derivados de oxadiazol con actividad sobre receptores s1p1
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
RU2402553C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20011089A1 (es) Tioamidas de oxazolidinona con sustituyentes de piperazin-amida
RU2008107727A (ru) Макроциклические ингибиторы вируса гепатита с
PE20030200A1 (es) Bencimidazol como inhibidores de las map quinasas
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
RU2005106846A (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
PE20050326A1 (es) Derivados de dioxido de tiazol-benzoisotiazol sustituidos como inhibidores de la actividad de la fosfatasa fosfotirosina 1b (ptp1b)
RU2005117964A (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
PE20041080A1 (es) Preparacion de medicamentos derivados de indolina sustituidos con heterociclos
RU2006130000A (ru) Органические соединения
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales
RU2015117647A (ru) Новые производные пиразола
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed